Compare Natera Inc. Common Stock (NTRA) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ProShares UltraPro QQQ ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while ProShares UltraPro QQQ ETF trades at $71.72 (market cap $38.26B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ProShares UltraPro QQQ ETF for 25 Days on average.
| NTRA | TQQQ | |
|---|---|---|
Market Cap | $57.03B | $38.26B |
Volume | 1,131,157 | 38,965,303 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $87.22 |
52-Week Low | $179.42 | $37.89 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TQQQ trades at $78.81, down 1.0% on the day, with a bullish technical signal from moving averages but neutral oscillators. The leveraged ETF faces mixed sentiment with recent articles highlighting both strong performance during the AI boom and concerns about hidden costs and volatility decay. Support levels are established at $77-$79, with resistance at $81-$82.
The outlook remains volatile with 3x leverage amplifying both gains and losses. Key risks include expense ratios beyond the stated 0.82% and market volatility amplification. Institutional activity shows mixed positioning, with some firms reducing stakes while others add exposure to tech and AI themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
